Effectiveness of BNT162b2 mRNA COVID-19 vaccine against SARS-CoV-2 variant Beta (B.1.351) among persons identified through contact tracing in Israel: A prospective cohort study

Shepherd R. Singer, Frederick J. Angulo, David L. Swerdlow, John M. McLaughlin, Itay Hazan, Netanel Ginish, Emilia Anis, Ella Mendelson, Orna Mor, Neta S. Zuckerman, Oran Erster, Jo Southern, Kaijie Pan, Gabriel Mircus, Marc Lipsitch, Eric J. Haas, Luis Jodar, Yeheskel Levy, Sharon Alroy-Preis^*

^*Corresponding author for this work

School of Public Health
Epidemiology & Preventive Medicine

Ministry of Health, Israel
Hebrew University of Jerusalem
Pfizer
Ministry of Defence, Government of Israel
Sheba Medical Center at Tel Hashomer
Tel Aviv University
Pfizer Pharmaceuticals Israel
Harvard University
Ben-Gurion University of the Negev

Research output: Contribution to journal › Article › peer-review

20 Scopus citations

Sort by
Weight
Alphabetically

Effectiveness of BNT162b2 mRNA COVID-19 vaccine against SARS-CoV-2 variant Beta (B.1.351) among persons identified through contact tracing in Israel: A prospective cohort study

Fingerprint

Keyphrases

Medicine and Dentistry

Pharmacology, Toxicology and Pharmaceutical Science

Immunology and Microbiology

Agricultural and Biological Sciences